• Jacob Calvert, Jana Hoffman, Christopher Barton, David Shimabukuro, Michael Ries, Uli Chettipally, Yaniv Kerem, Melissa Jay, Samson Mataraso, and Ritankar Das.
• a Dascena Inc. , Hayward , CA , USA.
• J Med Econ. 2017 Jun 1; 20 (6): 646-651.

AimsTo compute the financial and mortality impact of InSight, an algorithm-driven biomarker, which forecasts the onset of sepsis with minimal use of electronic health record data.MethodsThis study compares InSight with existing sepsis screening tools and computes the differential life and cost savings associated with its use in the inpatient setting. To do so, mortality reduction is obtained from an increase in the number of sepsis cases correctly identified by InSight. Early sepsis detection by InSight is also associated with a reduction in length-of-stay, from which cost savings are directly computed.ResultsInSight identifies more true positive cases of severe sepsis, with fewer false alarms, than comparable methods. For an individual ICU with 50 beds, for example, it is determined that InSight annually saves 75 additional lives and reduces sepsis-related costs by $560,000.LimitationsInSight performance results are derived from analysis of a single-center cohort. Mortality reduction results rely on a simplified use case, which fixes prediction times at 0, 1, and 2 h before sepsis onset, likely leading to under-estimates of lives saved. The corresponding cost reduction numbers are based on national averages for daily patient length-of-stay cost.ConclusionsInSight has the potential to reduce sepsis-related deaths and to lead to substantial cost savings for healthcare facilities.

23 keywords...

hide…